{"id":"W4361305093","doi":"10.2196/46101","title":"Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial","year":2023,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"General Hospital of People’s Liberation Army; Asahi Kasei Pharma Corporation","keywords":"Medicine; Mizoribine; Adverse effect; Nephrotic syndrome; Randomized controlled trial; Internal medicine; Clinical trial; Cyclophosphamide; Refractory (planetary science); Pediatrics; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03615312,0.007409404,0.01081553,0.002254941,0.00421169,0.004094491,0.004352719,0.006959721,0.0377715],"category_scores_gemma":[0.02854418,0.002868379,0.005394194,0.00308637,0.004345267,0.00395351,0.001897857,0.008229156,0.006570749],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005031055,"about_ca_system_score_gemma":0.01721523,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001951098,"about_ca_topic_score_gemma":0.004413117,"domain_scores_codex":[0.9752593,0.01633284,0.002593842,0.001884202,0.002057819,0.001871978],"domain_scores_gemma":[0.9848176,0.002918667,0.003674094,0.001955681,0.003951739,0.00268219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9471536,0.01257579,0.0008156797,0.01022962,0.002119021,0.0001683989,0.0002624028,0.001276252,0.002212958,0.002166389,0.008672422,0.01234747],"study_design_scores_gemma":[0.9633534,0.01920114,0.00139278,0.001084632,0.0008800887,0.00004406146,0.00008682561,0.001351731,0.0005448601,0.000896916,0.01109902,0.00006452436],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.003518536,0.0003049736,0.001148741,0.0002420479,0.0003148262,0.9927462,0.0009764271,0.00009381685,0.000654501],"genre_scores_gemma":[0.004157132,0.0001833527,0.002419646,0.0002610784,0.00008562057,0.992192,0.0003155562,0.000006838038,0.0003788322],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.0377715,"threshold_uncertainty_score":0.1911983,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2031537688589446,"score_gpt":0.5400446410829005,"score_spread":0.3368908722239559,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}